Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this Phase 2a study is to evaluate the maximal tolerated dose of
ANAVEX2-73 in patients with AD in a repeated-dose administration scheme, with the secondary
objectives being to explore the relationship between dosing regimen and pharmacodynamics
efficacy outcomes and to evaluate the bioavailability of the oral form used and to explore
the relationship of ANAVEX2-73 as add-on therapy to AD standard of care.